Log in
Analgesic-antipyretic

Paracetamol

Paracetamol (acetaminophen in the US) is a widely used analgesic and antipyretic agent with a favorable safety profile at therapeutic doses. Unlike NSAIDs, it lacks significant anti-inflammatory activity and does not inhibit platelet function. Its most important clinical consideration is dose-dependent hepatotoxicity in overdose, which is the leading cause of acute liver failure in many countries.

Practice questionsHigh-yield facts
Drug classAnalgesic-antipyretic, non-opioid
MechanismCentral COX inhibition, endocannabinoid modulation, exact mechanism debated
Main usesMild to moderate pain, fever
Key adverse effectHepatotoxicity in overdose (dose-dependent)
5 min readFor medical studentsUpdated 2026-10-15

Mechanism of action

The precise mechanism of paracetamol remains incompletely understood despite its century of clinical use. The primary proposed mechanisms include:

  • Central COX inhibition: Paracetamol preferentially inhibits cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis in the hypothalamus (antipyretic effect) and spinal cord (analgesic effect). It has minimal peripheral COX inhibition, explaining its lack of anti-inflammatory activity and gastric toxicity.
  • Endocannabinoid system modulation: Metabolism produces AM404, which inhibits anandamide reuptake and activates TRPV1 receptors, contributing to analgesia.
  • Serotonergic pathway activation: Descending serotonergic pain pathways may be enhanced.
  • Peroxidase activity: Paracetamol may reduce the oxidized form of COX enzymes more effectively in low-peroxide environments (CNS) than in inflamed peripheral tissues (high peroxide).

Unlike NSAIDs, paracetamol does not inhibit peripheral prostaglandin synthesis significantly, does not affect platelet aggregation, and does not cause gastric ulceration or renal impairment at therapeutic doses.

High-yield for exams
  • Paracetamol overdose causes hepatotoxicity via toxic metabolite NAPQI; N-acetylcysteine is the antidote
  • Unlike NSAIDs, paracetamol does not inhibit peripheral COX, cause GI ulcers, impair platelets, or worsen renal function
  • Maximum daily dose is 4 g/day in adults; exceeding this or overdose leads to dose-dependent liver necrosis
  • Chronic alcohol use increases hepatotoxicity risk via CYP2E1 induction and glutathione depletion
  • Paracetamol has no clinically significant anti-inflammatory activity, making it ineffective for inflammatory arthritis
  • Preferred analgesic-antipyretic in pregnancy; safe in peptic ulcer disease and bleeding disorders
  • Rumack-Matthew nomogram guides NAC treatment in acute single overdose; not applicable in staggered/chronic overdose
  • Chronic high-dose paracetamol may potentiate warfarin and increase INR

Indications

Paracetamol is indicated for:

  • Mild to moderate pain: Headache, dental pain, musculoskeletal pain, dysmenorrhea, postoperative pain
  • Fever reduction: In children and adults
  • Combination therapy: Often combined with opioids (codeine, hydrocodone, oxycodone) or NSAIDs for multimodal analgesia

Paracetamol is considered first-line for pain and fever in pregnancy and is preferred over NSAIDs in patients with peptic ulcer disease, bleeding disorders, or renal impairment. It does not provide meaningful anti-inflammatory effects for conditions like rheumatoid arthritis.

Pharmacokinetics

  • Absorption: Rapid and nearly complete oral absorption; peak plasma levels in 30-60 minutes
  • Distribution: Widely distributed; minimal protein binding (10-25%)
  • Metabolism: Primarily hepatic via conjugation
  • Therapeutic doses: 90% metabolized to non-toxic glucuronide and sulfate conjugates
  • Overdose: Saturation of conjugation pathways leads to increased metabolism via CYP2E1 to toxic metabolite NAPQI (N-acetyl-p-benzoquinone imine)
  • Excretion: Renal elimination of metabolites; half-life 2-3 hours in adults
  • Special populations: Neonates and infants have reduced glucuronidation capacity, relying more on sulfation

Adverse effects

At therapeutic doses, paracetamol is well tolerated with minimal adverse effects.

Common adverse effects

  • Generally very rare at recommended doses
  • Nausea (uncommon)

Serious adverse effects

  • Hepatotoxicity: Dose-dependent and the most clinically significant toxicity. Acute overdose (>7.5-10 g in adults, >150 mg/kg in children) causes hepatocellular necrosis via NAPQI accumulation. Presents with nausea, vomiting, and right upper quadrant pain within 24 hours, followed by elevated transaminases (peak 72-96 hours), coagulopathy, encephalopathy, and acute liver failure. Chronic supratherapeutic ingestion in alcoholics, malnourished patients, or those on CYP2E1 inducers carries increased risk.
  • Acute kidney injury: Rare; occurs in massive overdose or chronic high-dose use
  • Hypersensitivity reactions: Rare; includes rash, angioedema, anaphylaxis
  • Hematologic effects: Very rare cases of thrombocytopenia, agranulocytosis
  • Steven-Johnson syndrome/toxic epidermal necrolysis: Extremely rare

Paracetamol does not cause gastric ulceration, renal impairment at therapeutic doses, or platelet dysfunction, distinguishing it from NSAIDs.

Contraindications and warnings

Contraindications

  • Severe hepatic impairment or active liver disease
  • Hypersensitivity to paracetamol

Warnings and precautions

  • Chronic alcohol use: Increased risk of hepatotoxicity due to CYP2E1 induction and glutathione depletion; limit daily dose
  • Pre-existing liver disease: Use with caution; reduced dosing may be necessary
  • Malnutrition or fasting states: Depleted glutathione stores increase vulnerability to NAPQI toxicity
  • Maximum daily dose: Do not exceed 4 g/day in adults (some guidelines recommend 3 g/day maximum). Exceeding this increases hepatotoxicity risk even without acute overdose.
  • Multiple paracetamol-containing products: Many over-the-counter cold, flu, and pain medications contain paracetamol; patients may inadvertently exceed maximum daily dose
  • Pregnancy and lactation: Considered safe; first-line analgesic-antipyretic in pregnancy (FDA pregnancy category historically B, now no longer categorized). Excreted in breast milk in small amounts but considered compatible with breastfeeding.
  • G6PD deficiency: Theoretical risk of hemolysis, but clinical significance is debated; generally considered safe

Drug interactions

Paracetamol has relatively few clinically significant drug interactions compared to other analgesics.

  • Warfarin: Chronic high-dose paracetamol (>2 g/day for >1 week) may enhance anticoagulant effect and increase INR; mechanism unclear, possibly via COX-1 inhibition. Monitor INR if prolonged use.
  • CYP2E1 inducers: Chronic alcohol, isoniazid, rifampin, carbamazepine, phenytoin increase formation of toxic NAPQI metabolite, raising hepatotoxicity risk even at therapeutic doses.
  • Probenecid: May reduce paracetamol clearance, increasing plasma levels.
  • Cholestyramine: Reduces paracetamol absorption if given within 1 hour; separate administration.
  • Metoclopramide: Enhances paracetamol absorption rate (increases peak levels but not total bioavailability).

Paracetamol does not interact with most antibiotics, antihypertensives, or oral contraceptives, and does not displace highly protein-bound drugs (unlike NSAIDs).

Clinical pearls

  • Overdose management: N-acetylcysteine (NAC) is the antidote for paracetamol toxicity; it replenishes hepatic glutathione stores and provides an alternative substrate for NAPQI conjugation. NAC is most effective when started within 8 hours of ingestion but provides benefit even when delayed. Use the Rumack-Matthew nomogram to guide treatment decisions in acute single ingestions.
  • Asymptomatic early presentation: Patients may appear well in the first 24 hours post-overdose despite lethal ingestion; hepatotoxicity develops 24-72 hours later. Always measure paracetamol level at 4 hours post-ingestion or later for nomogram interpretation.
  • Chronic toxicity vs acute overdose: Repeated supratherapeutic doses over days ("staggered overdose") have worse outcomes than single acute overdose because patients present later and nomograms do not apply; treat with NAC based on clinical suspicion.
  • No anti-inflammatory effect: Paracetamol is ineffective for inflammatory arthritis, unlike NSAIDs. It is preferred in patients where NSAIDs are contraindicated: peptic ulcer disease, cardiovascular disease, renal impairment, bleeding risk.
  • Pediatric dosing safety: Parents often under- or overdose paracetamol in children due to confusion between infant drops and children's suspensions with different concentrations. Emphasize weight-based dosing.
  • Combination products: Many opioid-paracetamol combination products limit total daily opioid dose indirectly because exceeding paracetamol maximum (4 g/day) poses hepatotoxicity risk.
  • Intravenous formulation: Available for patients unable to take oral medications; same hepatotoxicity risk if dosing limits exceeded.
  • Alcoholics: Even therapeutic doses can cause hepatotoxicity in chronic alcoholics due to CYP2E1 induction and baseline glutathione depletion; recommend limiting to 2 g/day or avoiding entirely during active drinking.
Mnemonic

ACETAMINOPHEN toxicity antidote: N-ACETYLCYSTEINE (NAC replenishes glutathione to detoxify NAPQI)

Practice questions

1. A 22-year-old woman is brought to the emergency department 6 hours after ingesting 15 grams of paracetamol (acetaminophen) in a suicide attempt. She reports nausea but otherwise feels well. Vital signs are normal. Physical examination is unremarkable. Serum paracetamol level is 180 mcg/mL. Which of the following is the most appropriate immediate management?

Answer: C. This patient has a toxic paracetamol level at 6 hours post-ingestion (above 150 mcg/mL on the Rumack-Matthew nomogram) and requires immediate treatment with N-acetylcysteine (NAC), which replenishes glutathione and prevents hepatotoxicity. NAC is most effective within 8 hours but benefits patients even when delayed. Activated charcoal is only useful within 1-2 hours of ingestion. The patient is currently asymptomatic because hepatotoxicity develops 24-72 hours after ingestion; delaying treatment would be dangerous. Liver transplant evaluation is premature. Naloxone is an opioid antagonist and has no role here.

2. A 45-year-old man with chronic alcohol use disorder presents with right upper quadrant pain, nausea, and vomiting for 2 days. He reports taking 'extra-strength pain tablets' for back pain over the past week but cannot recall the exact amount. Laboratory studies show AST 4,500 U/L, ALT 3,800 U/L, INR 2.8, and creatinine 1.9 mg/dL. Serum paracetamol level is 15 mcg/mL. Which of the following best explains this patient's increased susceptibility to toxicity?

Answer: B. Chronic alcohol consumption induces CYP2E1, the enzyme that converts paracetamol to the toxic metabolite NAPQI. Alcoholics also have depleted hepatic glutathione stores from malnutrition and alcohol's direct effects, reducing capacity to detoxify NAPQI. This combination makes even therapeutic doses potentially hepatotoxic in chronic drinkers. The clinical picture shows severe hepatotoxicity (transaminases >1,000 U/L, coagulopathy) from a 'staggered overdose' over days. Paracetamol has minimal protein binding, does not significantly inhibit peripheral COX-2, and glucuronidation would be reduced (not increased) by alcohol, but the key mechanism is increased toxic metabolite formation plus reduced detoxification capacity.

3. A 6-year-old boy with juvenile idiopathic arthritis is brought for follow-up. His mother reports persistent joint pain and morning stiffness despite giving paracetamol 15 mg/kg every 6 hours for the past 3 weeks. Physical examination shows swelling and warmth of bilateral knees and wrists. Which of the following best explains the inadequate response to therapy?

Answer: C. Paracetamol lacks meaningful anti-inflammatory activity because it does not significantly inhibit peripheral cyclooxygenase enzymes or reduce prostaglandin synthesis in inflamed tissues. Juvenile idiopathic arthritis is an inflammatory condition requiring anti-inflammatory therapy, typically NSAIDs (ibuprofen, naproxen) or disease-modifying agents. Paracetamol may provide some analgesia and fever reduction but will not reduce joint inflammation, swelling, or stiffness. The dosing provided is appropriate (10-15 mg/kg per dose). Tolerance does not develop to paracetamol. This case illustrates a key clinical pearl: paracetamol is not appropriate monotherapy for inflammatory arthritis.

Frequently asked questions

How does paracetamol work?

Paracetamol works primarily by inhibiting cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis in the brain and spinal cord to provide pain relief and lower fever. It also modulates the endocannabinoid system and may activate descending serotonergic pain pathways. Unlike NSAIDs, it has minimal peripheral COX inhibition, which explains why it lacks anti-inflammatory effects and does not cause gastric ulcers or affect platelet function. The exact mechanism is still debated despite decades of use.

What are the side effects of paracetamol?

At recommended doses, paracetamol is very well tolerated with minimal side effects. The most serious adverse effect is dose-dependent hepatotoxicity, which occurs in overdose when the toxic metabolite NAPQI accumulates and causes liver cell death. Overdose can lead to acute liver failure, which is life-threatening. At therapeutic doses, side effects are rare and may include mild nausea. Unlike NSAIDs, paracetamol does not cause stomach ulcers, kidney damage, or bleeding problems when used as directed. Hypersensitivity reactions are extremely rare.

Is paracetamol safe during pregnancy?

Yes, paracetamol is considered safe during pregnancy and is the first-line analgesic and antipyretic for pregnant women. It has been used extensively in all trimesters without evidence of major teratogenic effects. However, pregnant women should use the lowest effective dose for the shortest duration necessary, and not exceed the maximum daily dose of 4 grams. Recent studies suggest possible associations with prolonged high-dose use and developmental outcomes, so prudent use is advised. Always consult a healthcare provider before taking any medication during pregnancy.

Paracetamol vs ibuprofen — what is the difference?

Paracetamol and ibuprofen both treat pain and fever, but differ significantly. Ibuprofen is an NSAID with anti-inflammatory properties, making it better for inflammatory conditions like arthritis, sprains, and dental pain with swelling. Paracetamol lacks meaningful anti-inflammatory effects. Paracetamol is safer for the stomach and does not increase bleeding risk or affect kidney function at therapeutic doses, making it preferred in patients with ulcers, kidney disease, or on blood thinners. Ibuprofen should be avoided in pregnancy (especially third trimester), while paracetamol is considered safe. Both are effective antipyretics.

What is the antidote for paracetamol overdose?

N-acetylcysteine (NAC) is the antidote for paracetamol overdose. NAC works by replenishing glutathione stores in the liver, which detoxifies the toxic metabolite NAPQI that accumulates in overdose and causes liver damage. NAC is most effective when given within 8 hours of overdose, but still provides significant benefit even when started later, up to 24 hours or beyond in certain cases. It can be given orally or intravenously. Treatment decisions are guided by the Rumack-Matthew nomogram for acute single ingestions, plotting serum paracetamol levels against time since ingestion.

Conditions it is used for

Pain (mild to moderate)HeadacheFeverDental painMusculoskeletal painDysmenorrheaPostoperative painOsteoarthritis (limited efficacy)
IbuprofenNaproxenAspirinDiclofenacCodeineTramadolN-acetylcysteineCelecoxib

Sources and further reading

DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N02BE01

Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.